Granules India Ltd SHARE PRICE [LIVE]
| Open: | |
| High: | |
| Low: |
| MKT Cap: | |
| 52-wk High: | |
| 52-wk Low: |
| Prev close: | |
| P/E: | |
| Div yield: |
Fundamental analysis
What is not working for the company?
What is working for the company?
| Name | Dec 22 | Oct 22 |
|---|---|---|
| Promoters (Change:-0.00) | 42.02% | 42.02% |
| FIIs (Change:1.02) | 23.67% | 22.65% |
| Mutual Funds (Change:0.53) | 3.91% | 3.38% |
| Insurance Companies (Change:-0.00) | 0.84% | 0.84% |
| Other DIIs (Change:0.00) | -0% | 0% |
| Non Institution (Change:-1.54) | 29.56% | 31.1% |
Similar Stocks
Return Calculator
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Granules India Ltd
Months ago
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
GRANULES News
Frequently Asked Questions
What is the Share price of GRANULES INDIA LTD. (GRANULES)?
Can I buy GRANULES INDIA LTD. (GRANULES) shares?
How do I buy GRANULES INDIA LTD. (GRANULES) from Angel One?
- Direct investment: You can buy GRANULES INDIA LTD. (GRANULES) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to GRANULES INDIA LTD. (GRANULES) shares.
In which sector do GRANULES INDIA LTD. (GRANULES) belong?
Is Granules India a Debt free Company?
No, Granules India is not a debt free company.
What is the main business of Granules India?
The main business of Granules India is to produce and sell several high-quality pharmaceutical products, such as Active Pharmaceutical Ingredients (API), Finished doses (FD), and Pharmaceutical Formulation Intermediates (PFI) across India, North America, Europe, and Latin America.
Who are the promoters of Granules India?
Some of the top promoters of Granules India are Krishna Prasad Chigurupati, Chigurupati Uma Devi, Tyche Investments Private Imited, Pragnya Chigurupati, Chigurupati Priyanka, Santhi Sree Ramanavarapu, Suseela Devi Chigurupati, Nikhila Reddy Yedaguri, Harsha Chigurupati, and Venkata Mahesh Krishna Narra.
What are the Subsidiaries that comes under Granules India?
Some of the wholly owned subsidiaries that come under Granules India are Granules USA, Inc., Granules Pharmaceuticals, Inc., Granules Europe Limited, and Granules Life Sciences Private Limited.
About GRANULES
Today's live share price for Granules India Ltd is NSE: ₹ 283.65, BSE: ₹ 282.55 with a current market capitalization of .
Incorporated as a private limited company in 1991, Granules India (GIL) was converted into a public limited company in Feb.'93. It commenced its operations in Apr.'91 as a merchant exporter of bulk drugs like paracetamol, guaifenesin and chloro pheniramine maleate. The company exports to the US, Europe, Mexico and Hongkong. Since 1992, GIL concentrated on export of paracetamol powder. In Aug.'94, GIL took over Triton Laboratories (TL), a group company from which GIL was procuring the drugs for exports. GIL also acquired a sick unit which was manufacturing bulk drugs, from the Andhra Pradesh State Financial Corporation (APSFC) in Mar.'94. GIL implemented the ongoing project taken over from TL to manufacture bulk drugs like folic acid, salbutamol sulphate, brom pheniramine maleate and direct compression (DC) blends of paracetamol, through the process of granulation. The unit, an EOU, is located at Hyderabad, Andhra Pradesh. Commercial production of folic acid commenced in Aug.'95. It came out with a public issue in Sep.'95 to part-finance this project. Company has completed expansion of Guaifenesin capacity from 100 Mts to 240 Mts per annum. Company had developing new products like Brom Pheniramine Maleate & Chloro Pheniramine Maleate, & is in process of developing new bulk drug for the export market. Company is very much hopeful about company's performance due to expansion of project will be completed in the current year. The Company set up a 100% marketing subsidiary in US to enhance its exposure in the large pharmaceutical market in the world. The Gagillapur plant commences its commercial production of Line II(installed capacity 3200 MT) which was commenced its July,2003 and the remaining 4000 MTPA is expected to go on stream in the first half of 2003-04. The total project cost is Rs.30 crore.
Read more
